Kv3.3 subunits control presynaptic action potential waveform and neurotransmitter release at a central excitatory synapse
- University of Leicester, United Kingdom
- Ludwig-Maximilians-Universität München, Germany
- Istituto di Ricerca Pediatrica Citta'della Speranza, Italy
- University of Stirling, United Kingdom
Abstract
Kv3 potassium currents mediate rapid repolarization of action potentials (APs), supporting fast spikes and high repetition rates. Of the four Kv3 gene family members, Kv3.1 and Kv3.3 are highly expressed in the auditory brainstem and we exploited this to test for subunit-specific roles at the calyx of Held presynaptic terminal in the mouse. Deletion of Kv3.3 (but not Kv3.1) reduced presynaptic Kv3 channel immunolabelling, increased presynaptic AP duration and facilitated excitatory transmitter release; which in turn enhanced short-term depression during high frequency transmission. The response to sound was delayed in the Kv3.3KO, with higher spontaneous and lower evoked firing, thereby reducing signal-to-noise ratio. Computational modelling showed that the enhanced EPSC and short-term depression in the Kv3.3KO reflected increased vesicle release probability and accelerated activity-dependent vesicle replenishment. We conclude that Kv3.3 mediates fast repolarization for short precise APs, conserving transmission during sustained high-frequency activity at this glutamatergic excitatory synapse.
Data availability
Data generated in this study are included in the manuscript and supporting files. Source data files for each figure has been uploaded onto FigShare. Datasets Generated for the Ms "Kv3.3 subunits control presynaptic action potential waveform and neurotransmitter release at a central excitatory synapse" Authors: Ian D. Forsythe, Amy Richardson, Victoria Ciampani, Mihai Stancu, Kseniia Bondarenko, Sherylanne Newton, Joern Steinert, Nadia Pilati, Bruce Graham, Conny Kopp-Scheinpflug, 2022,https://figshare.com/s/9c0a07ed2fe5761cc281. The model code and associated data files are available at: Bruce Graham, 2021, https://github.com/bpgraham/CoH-Models
Article and author information
Author details
Funding
Biotechnology and Biological Sciences Research Council (R001154/1)
- Ian D Forsythe
Biotechnology and Biological Sciences Research Council (Case Award M016501)
- Ian D Forsythe
H2020 Health (ITN LISTEN 722098)
- Ian D Forsythe
Deutsche Forschungsgemeinschaft (DFG SFB870 A-10)
- Conny Kopp-Scheinpflug
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: Experiments were conducted in accordance with the Animals (Scientific Procedures) Act UK 1986 and as revised by the European Directive 2010/63/EU on the protection of animals used for scientific purposes. All procedures were approved by national oversight bodies (UK Home Office, or Bavarian district government, ROB-55.2-2532.Vet_02-18-1183) and the local animal research ethics review committees. In vivo experiments were conducted under anaesthesia: with a subcutaneous injection of 0.01ml/g MMF (0.5mg/kg body weight Medetomidine, 5.0mg/kg body weight Midazolam and 0.05mg/kg body weight Fentanyl). Every effort was made to minimise suffering and at the end of each procedure the animal was humanely killed using an approved method.
Copyright
© 2022, Richardson et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,660
- views
-
- 305
- downloads
-
- 23
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Kv3.3 subunits control presynaptic action potential waveform and neurotransmitter release at a central excitatory synapse
eLife 11:e75219.
https://doi.org/10.7554/eLife.75219
Further reading
-
- Neuroscience
Gamma oscillations in brain activity (30–150 Hz) have been studied for over 80 years. Although in the past three decades significant progress has been made to try to understand their functional role, a definitive answer regarding their causal implication in perception, cognition, and behavior still lies ahead of us. Here, we first review the basic neural mechanisms that give rise to gamma oscillations and then focus on two main pillars of exploration. The first pillar examines the major theories regarding their functional role in information processing in the brain, also highlighting critical viewpoints. The second pillar reviews a novel research direction that proposes a therapeutic role for gamma oscillations, namely the gamma entrainment using sensory stimulation (GENUS). We extensively discuss both the positive findings and the issues regarding reproducibility of GENUS. Going beyond the functional and therapeutic role of gamma, we propose a third pillar of exploration, where gamma, generated endogenously by cortical circuits, is essential for maintenance of healthy circuit function. We propose that four classes of interneurons, namely those expressing parvalbumin (PV), vasointestinal peptide (VIP), somatostatin (SST), and nitric oxide synthase (NOS) take advantage of endogenous gamma to perform active vasomotor control that maintains homeostasis in the neuronal tissue. According to this hypothesis, which we call GAMER (GAmma MEdiated ciRcuit maintenance), gamma oscillations act as a ‘servicing’ rhythm that enables efficient translation of neural activity into vascular responses that are essential for optimal neurometabolic processes. GAMER is an extension of GENUS, where endogenous rather than entrained gamma plays a fundamental role. Finally, we propose several critical experiments to test the GAMER hypothesis.
-
- Neuroscience
Motivation depends on dopamine, but might be modulated by acetylcholine which influences dopamine release in the striatum, and amplifies motivation in animal studies. A corresponding effect in humans would be important clinically, since anticholinergic drugs are frequently used in Parkinson’s disease, a condition that can also disrupt motivation. Reward and dopamine make us more ready to respond, as indexed by reaction times (RT), and move faster, sometimes termed vigour. These effects may be controlled by preparatory processes that can be tracked using electroencephalography (EEG). We measured vigour in a placebo-controlled, double-blinded study of trihexyphenidyl (THP), a muscarinic antagonist, with an incentivised eye movement task and EEG. Participants responded faster and with greater vigour when incentives were high, but THP blunted these motivational effects, suggesting that muscarinic receptors facilitate invigoration by reward. Preparatory EEG build-up (contingent negative variation [CNV]) was strengthened by high incentives and by muscarinic blockade, although THP reduced the incentive effect. The amplitude of preparatory activity predicted both vigour and RT, although over distinct scalp regions; frontal activity predicted vigour, whereas a larger, earlier, central component predicted RT. The incentivisation of RT was partly mediated by the CNV, though vigour was not. Moreover, the CNV mediated the drug’s effect on dampening incentives, suggesting that muscarinic receptors underlie the motivational influence on this preparatory activity. Taken together, these findings show that a muscarinic blocker impairs motivated action in healthy people, and that medial frontal preparatory neural activity mediates this for RT.
